# West Pharmaceutical Services Inc: financial statements, quarterly WST · NYSE · CIK 105770 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/wst.md) · [Financials](/companies/wst/financials.md) · [Filings](/companies/wst/filings.md) · [Insiders](/companies/wst/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/wst/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [732 d](/filings/0000105770-26-000010.md) | [695](/filings/0000105770-25-000036.md) | [702](/filings/0000105770-25-000065.md) | [747](/filings/0000105770-25-000093.md) | [749 d](/filings/0000105770-26-000010.md) | [698](/filings/0000105770-26-000049.md) | [767](/filings/0000105770-26-000099.md) | [805](/filings/0000105770-26-000121.md) | [805 d](/filings/0000105770-26-000010.md) | [845](/filings/0000105770-26-000049.md) | [872](/filings/0000105770-26-000099.md) | [875](/filings/0000105770-26-000121.md) | | Cost of revenue | $m | [454 d](/filings/0000105770-26-000010.md) | [465](/filings/0000105770-25-000036.md) | [472](/filings/0000105770-25-000065.md) | [482](/filings/0000105770-25-000093.md) | [475 d](/filings/0000105770-26-000010.md) | [466](/filings/0000105770-26-000049.md) | [493](/filings/0000105770-26-000099.md) | [510](/filings/0000105770-26-000121.md) | [501 d](/filings/0000105770-26-000010.md) | [549](/filings/0000105770-26-000049.md) | [543](/filings/0000105770-26-000099.md) | [527](/filings/0000105770-26-000121.md) | | Gross profit | $m | [278 d](/filings/0000105770-26-000010.md) | [230](/filings/0000105770-25-000036.md) | [230](/filings/0000105770-25-000065.md) | [265](/filings/0000105770-25-000093.md) | [274 d](/filings/0000105770-26-000010.md) | [232](/filings/0000105770-26-000049.md) | [274](/filings/0000105770-26-000099.md) | [294](/filings/0000105770-26-000121.md) | [304 d](/filings/0000105770-26-000010.md) | [296](/filings/0000105770-26-000049.md) | [329](/filings/0000105770-26-000099.md) | [347](/filings/0000105770-26-000121.md) | | Research and development | $m | [18.4 d](/filings/0000105770-26-000010.md) | [17.6](/filings/0000105770-25-000036.md) | [17.5](/filings/0000105770-25-000065.md) | [15.5](/filings/0000105770-25-000093.md) | [18.5 d](/filings/0000105770-26-000010.md) | [16.3](/filings/0000105770-26-000049.md) | [19.1](/filings/0000105770-26-000099.md) | [17.1](/filings/0000105770-26-000121.md) | [21.8 d](/filings/0000105770-26-000010.md) | [15.8](/filings/0000105770-26-000049.md) | [19.7](/filings/0000105770-26-000099.md) | [18.3](/filings/0000105770-26-000121.md) | | Selling, general and administrative | $m | [90.0 d](/filings/0000105770-26-000010.md) | [86.7](/filings/0000105770-25-000036.md) | [83.0](/filings/0000105770-25-000065.md) | [83.5](/filings/0000105770-25-000093.md) | [85.3 d](/filings/0000105770-26-000010.md) | [88.0](/filings/0000105770-26-000049.md) | [95.9](/filings/0000105770-26-000099.md) | [103](/filings/0000105770-26-000121.md) | [107 d](/filings/0000105770-26-000010.md) | [99.5](/filings/0000105770-26-000049.md) | [118](/filings/0000105770-26-000099.md) | [113](/filings/0000105770-26-000121.md) | | Operating income | $m | [161 d](/filings/0000105770-26-000010.md) | [123](/filings/0000105770-25-000036.md) | [126](/filings/0000105770-25-000065.md) | [161](/filings/0000105770-25-000093.md) | [160 d](/filings/0000105770-26-000010.md) | [107](/filings/0000105770-26-000049.md) | [154](/filings/0000105770-26-000099.md) | [168](/filings/0000105770-26-000121.md) | [157 d](/filings/0000105770-26-000010.md) | [177](/filings/0000105770-26-000049.md) | [179](/filings/0000105770-26-000099.md) | [267](/filings/0000105770-26-000121.md) | | Interest expense | $m | [1.2 d](/filings/0000105770-24-000015.md) | [1.6](/filings/0000105770-24-000031.md) | [1.5](/filings/0000105770-25-000065.md) | [0.7](/filings/0000105770-24-000081.md) | [(0.8) d](/filings/0000105770-26-000010.md) | [0.4](/filings/0000105770-26-000049.md) | [0.1](/filings/0000105770-26-000099.md) | [0.2](/filings/0000105770-26-000121.md) | [(0.2) d](/filings/0000105770-26-000010.md) | [1.9](/filings/0000105770-26-000049.md) | [2.6](/filings/0000105770-26-000099.md) | [3.8](/filings/0000105770-26-000121.md) | | Income tax | $m | [34.5 d](/filings/0000105770-26-000010.md) | [16.4](/filings/0000105770-25-000036.md) | [21.9](/filings/0000105770-25-000065.md) | [32.4](/filings/0000105770-25-000093.md) | [36.8 d](/filings/0000105770-26-000010.md) | [24.1](/filings/0000105770-26-000049.md) | [30.2](/filings/0000105770-26-000099.md) | [34.0](/filings/0000105770-26-000121.md) | [33.3 d](/filings/0000105770-26-000010.md) | [44.7](/filings/0000105770-26-000049.md) | [32.2](/filings/0000105770-26-000099.md) | [58.0](/filings/0000105770-26-000121.md) | | Net income | $m | [137 d](/filings/0000105770-26-000010.md) | [115](/filings/0000105770-25-000093.md) | [111](/filings/0000105770-25-000093.md) | [136](/filings/0000105770-25-000093.md) | [130 d](/filings/0000105770-26-000010.md) | [89.8](/filings/0000105770-26-000121.md) | [132](/filings/0000105770-26-000121.md) | [140](/filings/0000105770-26-000121.md) | [132 d](/filings/0000105770-26-000010.md) | [139](/filings/0000105770-26-000121.md) | [154](/filings/0000105770-26-000121.md) | [214](/filings/0000105770-26-000121.md) | | Diluted EPS | $ per share | not reported | [1.55](/filings/0000105770-25-000036.md) | [1.51](/filings/0000105770-25-000065.md) | [1.85](/filings/0000105770-25-000093.md) | not reported | [1.23](/filings/0000105770-26-000049.md) | [1.82](/filings/0000105770-26-000099.md) | [1.92](/filings/0000105770-26-000121.md) | not reported | [1.92](/filings/0000105770-26-000049.md) | [2.15](/filings/0000105770-26-000099.md) | [3.02](/filings/0000105770-26-000121.md) | | Basic EPS | $ per share | not reported | [1.57](/filings/0000105770-25-000036.md) | [1.52](/filings/0000105770-25-000065.md) | [1.87](/filings/0000105770-25-000093.md) | not reported | [1.24](/filings/0000105770-26-000049.md) | [1.82](/filings/0000105770-26-000099.md) | [1.94](/filings/0000105770-26-000121.md) | not reported | [1.93](/filings/0000105770-26-000049.md) | [2.17](/filings/0000105770-26-000099.md) | [3.04](/filings/0000105770-26-000121.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [854](/filings/0000105770-25-000013.md) | [602](/filings/0000105770-24-000031.md) | [446](/filings/0000105770-24-000066.md) | [491](/filings/0000105770-24-000081.md) | [485](/filings/0000105770-26-000010.md) | [404](/filings/0000105770-25-000036.md) | [510](/filings/0000105770-25-000065.md) | [629](/filings/0000105770-25-000093.md) | [791](/filings/0000105770-26-000121.md) | [521](/filings/0000105770-26-000049.md) | [436](/filings/0000105770-26-000099.md) | [464](/filings/0000105770-26-000121.md) | | Current assets | $m | [1,936](/filings/0000105770-25-000013.md) | [1,693](/filings/0000105770-24-000031.md) | [1,483](/filings/0000105770-24-000066.md) | [1,551](/filings/0000105770-24-000081.md) | [1,538](/filings/0000105770-26-000010.md) | [1,458](/filings/0000105770-25-000036.md) | [1,681](/filings/0000105770-25-000065.md) | [1,823](/filings/0000105770-25-000093.md) | [1,978](/filings/0000105770-26-000121.md) | [1,827](/filings/0000105770-26-000049.md) | [1,808](/filings/0000105770-26-000099.md) | [1,817](/filings/0000105770-26-000121.md) | | Total assets | $m | [3,830](/filings/0000105770-25-000013.md) | [3,602](/filings/0000105770-24-000031.md) | [3,489](/filings/0000105770-24-000066.md) | [3,675](/filings/0000105770-24-000081.md) | [3,643](/filings/0000105770-26-000010.md) | [3,618](/filings/0000105770-25-000036.md) | [3,953](/filings/0000105770-25-000065.md) | [4,106](/filings/0000105770-25-000093.md) | [4,270](/filings/0000105770-26-000121.md) | [4,110](/filings/0000105770-26-000049.md) | [4,076](/filings/0000105770-26-000099.md) | [4,061](/filings/0000105770-26-000121.md) | | Current liabilities | $m | [672](/filings/0000105770-25-000013.md) | [648](/filings/0000105770-24-000031.md) | [634](/filings/0000105770-24-000066.md) | [517](/filings/0000105770-24-000081.md) | [550](/filings/0000105770-26-000010.md) | [527](/filings/0000105770-25-000036.md) | [605](/filings/0000105770-25-000065.md) | [635](/filings/0000105770-25-000093.md) | [655](/filings/0000105770-26-000121.md) | [674](/filings/0000105770-26-000049.md) | [641](/filings/0000105770-26-000099.md) | [644](/filings/0000105770-26-000121.md) | | Total liabilities | $m | [949](/filings/0000105770-25-000013.md) | [922](/filings/0000105770-24-000031.md) | [913](/filings/0000105770-24-000066.md) | [923](/filings/0000105770-24-000081.md) | [961](/filings/0000105770-26-000010.md) | [935](/filings/0000105770-25-000036.md) | [1,024](/filings/0000105770-25-000065.md) | [1,054](/filings/0000105770-25-000093.md) | [1,094](/filings/0000105770-26-000121.md) | [1,119](/filings/0000105770-26-000049.md) | [1,086](/filings/0000105770-26-000099.md) | [1,093](/filings/0000105770-26-000121.md) | | Long-term debt | $m | [72.8](/filings/0000105770-25-000013.md) | [72.8](/filings/0000105770-24-000031.md) | [72.9](/filings/0000105770-24-000066.md) | [203](/filings/0000105770-24-000081.md) | [203](/filings/0000105770-26-000010.md) | [203](/filings/0000105770-25-000036.md) | [203](/filings/0000105770-25-000065.md) | [203](/filings/0000105770-25-000093.md) | [203](/filings/0000105770-26-000121.md) | [203](/filings/0000105770-26-000049.md) | [203](/filings/0000105770-26-000099.md) | [203](/filings/0000105770-26-000121.md) | | Current portion of debt | $m | [134](/filings/0000105770-25-000013.md) | [133](/filings/0000105770-24-000031.md) | [133](/filings/0000105770-24-000066.md) | [0.0](/filings/0000105770-24-000081.md) | [0.0](/filings/0000105770-26-000010.md) | [0.0](/filings/0000105770-25-000036.md) | [0.0](/filings/0000105770-25-000065.md) | [0.0](/filings/0000105770-25-000093.md) | [0.0](/filings/0000105770-26-000121.md) | [0.0](/filings/0000105770-26-000049.md) | [0.0](/filings/0000105770-26-000099.md) | [0.0](/filings/0000105770-26-000121.md) | | Shareholders' equity | $m | [2,881](/filings/0000105770-26-000010.md) | [2,681](/filings/0000105770-25-000093.md) | [2,577](/filings/0000105770-25-000093.md) | [2,752](/filings/0000105770-25-000093.md) | [2,682](/filings/0000105770-26-000121.md) | [2,683](/filings/0000105770-26-000121.md) | [2,929](/filings/0000105770-26-000121.md) | [3,052](/filings/0000105770-26-000121.md) | [3,176](/filings/0000105770-26-000121.md) | [2,990](/filings/0000105770-26-000121.md) | [2,990](/filings/0000105770-26-000121.md) | [2,968](/filings/0000105770-26-000121.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [239 d](/filings/0000105770-26-000010.md) | [118](/filings/0000105770-25-000036.md) | [165 d](/filings/0000105770-25-000065.md) | [180 d](/filings/0000105770-25-000093.md) | [190 d](/filings/0000105770-26-000010.md) | [129](/filings/0000105770-26-000049.md) | [177 d](/filings/0000105770-26-000099.md) | [197 d](/filings/0000105770-26-000121.md) | [251 d](/filings/0000105770-26-000010.md) | [89.9](/filings/0000105770-26-000049.md) | [124 d](/filings/0000105770-26-000099.md) | [190 d](/filings/0000105770-26-000121.md) | | Capital expenditure | $m | [109 d](/filings/0000105770-26-000010.md) | [90.6](/filings/0000105770-25-000036.md) | [100 d](/filings/0000105770-25-000065.md) | [81.3 d](/filings/0000105770-25-000093.md) | [105 d](/filings/0000105770-26-000010.md) | [71.3](/filings/0000105770-26-000049.md) | [75.2 d](/filings/0000105770-26-000099.md) | [63.3 d](/filings/0000105770-26-000121.md) | [76.1 d](/filings/0000105770-26-000010.md) | [42.7](/filings/0000105770-26-000049.md) | [43.2 d](/filings/0000105770-26-000099.md) | [39.1 d](/filings/0000105770-26-000121.md) | | Dividends paid | $m | [14.8 d](/filings/0000105770-26-000010.md) | [14.7](/filings/0000105770-25-000036.md) | [14.6 d](/filings/0000105770-25-000065.md) | [14.5 d](/filings/0000105770-25-000093.md) | [15.3 d](/filings/0000105770-26-000010.md) | [15.2](/filings/0000105770-26-000049.md) | [15.1 d](/filings/0000105770-26-000099.md) | [15.1 d](/filings/0000105770-26-000121.md) | [15.8 d](/filings/0000105770-26-000010.md) | [15.8](/filings/0000105770-26-000049.md) | [15.7 d](/filings/0000105770-26-000099.md) | [15.5 d](/filings/0000105770-26-000121.md) | | Share repurchases | $m | [177 d](/filings/0000105770-26-000010.md) | [267](/filings/0000105770-25-000036.md) | [187 d](/filings/0000105770-25-000065.md) | [52.4 d](/filings/0000105770-25-000093.md) | [54.4 d](/filings/0000105770-26-000010.md) | [134](/filings/0000105770-26-000049.md) | [0.5 d](/filings/0000105770-26-000099.md) | [0.0 d](/filings/0000105770-26-000121.md) | [0.0 d](/filings/0000105770-26-000010.md) | [298](/filings/0000105770-26-000049.md) | [157 d](/filings/0000105770-26-000099.md) | [231 d](/filings/0000105770-26-000121.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividendsCommonStock - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [75.7](/filings/0000105770-24-000031.md) | [75.4](/filings/0000105770-24-000066.md) | [75.3](/filings/0000105770-24-000081.md) | [74.3](/filings/0000105770-25-000036.md) | [73.7](/filings/0000105770-25-000065.md) | [73.4](/filings/0000105770-25-000093.md) | [73.0](/filings/0000105770-26-000049.md) | [72.5](/filings/0000105770-26-000099.md) | [72.6](/filings/0000105770-26-000121.md) | [72.4](/filings/0000105770-26-000049.md) | [71.3](/filings/0000105770-26-000099.md) | [70.8](/filings/0000105770-26-000121.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 69,661,036 at 2026-10-21, from the cover of the [10-Q filed 2026-10-29](/filings/0000105770-26-000121.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 18:13 ET. No prices; not investment advice.